Shenzhen Salubris Pharmaceuticals' (SHE:002294) unit, Salubris Biotherapeutics, presented the results of its clinical trial on the drug JK06 at the American Society of Clinical Oncology Annual Meeting, according to a Shenzhen bourse filing on Wednesday.
The trials showed that the drug has safety and efficacy in patients with tumors, including non-small cell lung cancer and breast cancer.
The trial enrolled 173 patients in Europe.
Shares of the pharmaceutical company were down 2% at the close.
The U.S. Trade Representative has concluded that 60 economies failed to properly ban or enforce restrictions on imports linked to forced labor, calling the practices harmful to fair global trade, the US Executive Office announced Tuesday.Among the Southeast Asian countries named are the Philippines, Thailand, Vietnam, Malaysia, Indonesia, Cambodia and Singapore. Taiwan is also included separately among the economies cited.The findings are part of a broader review of many economies. Officials said the gaps create unfair competition by helping producers who use forced labor.USTR has proposed additional tariffs of 10% to 12.5% on affected imports and is seeking public comments before finalizing any action, with hearings scheduled for July 2026.
Genscript Biotech's (HKG:1548) associate Legend Biotech will present preliminary clinical data for LB2501 at a late-breaking session at the European Hematology Association 2026 Congress, according to a Tuesday Hong Kong bourse filing.Shares of the cancer drug company were up nearly 11% in Wednesday afternoon trading.The data is for the drug being tested in patients with relapsed/refractory B-cell non-Hodgkin lymphoma.The conference will take place from June 11 to 14 in Stockholm, Sweden.
Jointown Pharmaceutical's (SHA:600998) subsidiary, Beijing Jingfeng Pharmaceutical (Shandong), received approval from China's National Medical Products Administration for the marketing of its active pharmaceutical ingredient, azelastine hydrochloride, according to a Shanghai bourse filing on Wednesday.The drug is a selective histamine H1 receptor antagonist with antihistamine and anti-allergic properties.